Liu JF, Barry WT, Birrer M, Lee JM, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol 2019;30:551-557.
PMID: 31987271